Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | HBB | P68871 | 1/20 | 0.56 |
| ▸ | PYGM | P11217 | 3/20 | 0.53 |
| ▸ | TK2 | O00142 | 6/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28113579 | 1.00 | LMNA (0.56) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL659076 | 1.00 | LMNA (0.56) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL4192644 | 0.90 | P2RY6 (0.51) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL7137093 | 0.89 | LMNA (0.56) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL22992480 | 0.87 | TK2 (0.67) | LMNAPYGMTK2 | |
| SCHEMBL62322 | 0.87 | TK2 (0.67) | LMNAPYGMTK2 | |
| SCHEMBL20875706 | 0.87 | TK2 (0.67) | LMNAPYGMTK2 | |
| SCHEMBL22992424 | 0.87 | TK2 (0.67) | LMNAPYGMTK2 | |
| SCHEMBL7182936 | 0.87 | TK2 (0.67) | LMNAPYGMTK2 | |
| SCHEMBL31685558 | 0.87 | PYGM (0.54) | PYGMTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | claimed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| US-20090307805-A1 | ALTERNATIVE NUCLEOTIDES FOR IMPROVED TARGETED NUCLEOTIDE EXCHANGE | KEYGENE N.V | 2009-12-10 | — | — | US | claimed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | UNIV CALIFORNIA (US) | 2021-10-28 | — | — | US | disclosed |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | disclosed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | disclosed |
| US-9410189-B2 | Methods of preventing non-specific reactions of nucleotide sequences | CO-DIAGNOSTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| EP-2319853-B1 | Process for the production of 2'-branched nucleosides | IDENIX PHARMACEUTICALS INC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | disclosed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| US-20030022150-A1 | Detecting preferential bioplymers in sample; obtain nutrient broths inoculate with cells, immerse electrodes, code cells, incubate cells with substrate, monitor response, evaluate response | AGILENT TECHNOLOGIES, INC. | 2003-01-30 | — | — | US | disclosed |
| US-6218118-B1 | MIXTURE OF NATURAL AND MASS-MODIFIED GENERIC OLIGONUCLEOTIDE PRECURSORS; USING MIXTURE AND ENZYMATIC PROCESSES TO ALTER THE LENGTH, AND THUS THE MASS, OF PRECURSORS THAT ARE COMPLEMENTARY TO TARGET NUCLEIC ACID | AGILENT TECHNOLOGIES, INC. | 2001-04-17 | — | — | US | disclosed |
| EP-1015643-A2 | METHOD AND REAGENTS FOR ANALYZING THE NUCLEOTIDE SEQUENCE OF NUCLEIC ACIDS | Hewlett-Packard Company (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-2000003038-A2 | METHOD AND REAGENTS FOR ANALYZING THE NUCLEOTIDE SEQUENCE OF NUCLEIC ACIDS | HEWLETT-PACKARD COMPANY (US) | 2000-01-20 | — | — | WO | disclosed |
| US-5459243-A | Apparatus and processes for the large scale generation and transfer of diazomethane | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | LMNA 3677/4885SMN1; SMN2 2496/4885TSHR 4148/4885 |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885SMN1; SMN2 3259/4885TSHR 4517/4885 |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885SMN1; SMN2 3259/4885TSHR 4517/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885SMN1; SMN2 3259/4885TSHR 4517/4885 |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885SMN1; SMN2 3259/4885TSHR 4517/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | LMNA 3677/4885SMN1; SMN2 2496/4885TSHR 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.